Concord Drugs Ltd vs Fermenta Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 85.13 as of 30 Apr 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 yearsThe P/E Ratio of Fermenta Biotech Ltd changed from 15.9 on March 2021 to 10.4 on March 2025 . This represents a CAGR of -8.14% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 yearsThe Market Cap of Fermenta Biotech Ltd changed from ₹ 736.66 crore on March 2021 to ₹ 805.08 crore on March 2025 . This represents a CAGR of 1.79% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Fermenta Biotech Ltd for the Dec '25 is ₹ 140.48 crore as compare to the Sep '25 revenue of ₹ 135.66 crore. This represent the growth of 3.55% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Fermenta Biotech Ltd for the Dec '25 is ₹ 25.89 crore as compare to the Sep '25 ebitda of ₹ 32.07 crore. This represent the decline of -19.27% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Fermenta Biotech Ltd changed from ₹ -5.93 crore to ₹ 12.02 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Fermenta Biotech Ltd changed from 13.87 % on March 2021 to 10.78 % on March 2025 . This represents a CAGR of -4.92% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Fermenta Biotech Ltd

Fermenta Biotech Limited was formerly incorporated as 'Duphar-Interfran Limited' in May, 1951.
The Company name was changed to 'DIL Limited' in September, 2003 and later on, was changed to 'Fermenta Biotech Limited' on October 17, 2019.
The Company is presently engaged in pharmaceuticals, manufacturing and marketing Active Pharmaceutical Ingredients, biotechnology, environmental solutions and renting of properties. Initially, Company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities.
It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London.
These collaborators participated in the equity capital of the Company to the extent of 25% each. In 1964, Company entered into a collaboration with Solvay Duphar to manufacture vitamin D3.

FAQs for the comparison of Concord Drugs Ltd and Fermenta Biotech Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Fermenta Biotech Ltd?

Market cap of Concord Drugs Ltd is 112 Cr while Market cap of Fermenta Biotech Ltd is 916 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Fermenta Biotech Ltd?

The stock performance of Concord Drugs Ltd and Fermenta Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Fermenta Biotech Ltd?

As of May 3, 2026, the Concord Drugs Ltd stock price is INR ₹85.13. On the other hand, Fermenta Biotech Ltd stock price is INR ₹311.4.

How do dividend payouts of Concord Drugs Ltd and Fermenta Biotech Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Fermenta Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.